Ratings Moves: HVB,...
Health Care: Health Services
Mela Sciences Inc. (MELA: NASDAQ)
$1.08 -0.01 | -0.92%
05/22/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 278.46K | 0.00 | 0.00 | 0.00 |
| Cost of Sales | 1.07M | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | -794.37K | 0.00 | 0.00 | 0.00 |
| Selling, General, and Administrative Expenses | 14.17M | 10.81M | 8.74M | 7.63M |
| Research & Development | 6.79M | 9.66M | 11.50M | 10.95M |
| Operating Income before D & A (EBITDA) | -21.76M | -20.46M | -20.23M | -18.58M |
| Depreciation & Amortization | 969.50K | 562.80K | 552.86K | 314.35K |
| Interest Income | 32.03K | 54.37K | 31.58K | 45.26K |
| Other Income - Net | 20.00K | 23.14K | 280.74K | 83.26K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -22.67M | -20.95M | -20.48M | -18.77M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Pre-Tax Income | -22.67M | -20.95M | -20.48M | -18.77M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -22.67M | 0.00 | 0.00 | -18.45M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -22.67M | 0.00 | 0.00 | -18.45M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -22.67M | -20.38M | -19.92M | -18.45M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-22.67M | 0.00 | 0.00 | -18.45M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -22.67M | 0.00 | 0.00 | -18.45M |
| Basic EPS from Continuing Ops. | -0.74 | -0.80 | -0.83 | -0.96 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.74 | -0.80 | -0.83 | -0.96 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.74 | -0.80 | -0.83 | -0.96 |
| Basic Normalized Net Income/Share | -0.74 | n.a. | n.a. | -0.96 |
| EPS fr Continuing Ops. | -0.74 | -0.80 | -0.83 | -0.96 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.74 | -0.80 | -0.83 | -0.96 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.74 | -0.80 | -0.83 | -0.96 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.74 | n.a. | n.a. | -0.96 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with MELA
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor5 Stocks Under-$10 Setting ...
- ContributorBreakout Stocks Of The Week...
- UserMy Portfolio
- UserThe pick
- Usergrn8nrg Portfolio 1
Latest MELA Headlines from TheStreet
- MELA Sciences Announces First Quarter 2013 Financial Results 04.30.13 | 04:04 pm
- 5 Stocks Under $10 Set to Soar 04.25.13 | 01:04 pm
- MELA Sciences To Host Investor Meeting In Conjunction With Melanoma Monday On May 6th 2013 In New York 04.18.13 | 04:04 pm
- MELA Sciences To Participate In Upcoming 12th Annual Needham Healthcare Conference 04.15.13 | 04:04 pm
- MELA Sciences To Release First Quarter 2013 Financial Results And Host Conference Call On Tuesday, April 30, 2013 04.10.13 | 04:04 pm
- MELA Sciences Announces Fourth Quarter And Year End 2012 Financial Results 03.05.13 | 04:03 pm
- MELA Sciences Prices Public Offering Of Common Stock; Termination Of At The Market (ATM) Equity Offering Program; And Execution Of Term Sheet For Debt Financing 02.12.13 | 08:02 am
- MELA Sciences To Release Fourth Quarter And Year End 2012 Financial Results And Host Conference Call On Tuesday, March 5, 2013 02.04.13 | 08:02 am
- MELA Sciences To Present At Upcoming Investor Conferences 01.28.13 | 08:01 am
- 4 Biotech Stocks Spiking on Unusual Volume 01.08.13 | 02:01 pm
Press Releases for MELA
- MELA Sciences, Inc. Rings NASDAQ Opening Bell With Leading Dermatologists To Raise Awareness For Melanoma Detection And Prevention - PR Newswire 05.06.13 | 09:05 am
- MELA Sciences, Inc. Partners With Dermatologists Nationwide To Promote Skin Cancer Awareness - PR Newswire 04.23.13 | 08:04 am
- MELA Sciences, Inc. Presents New Data That Reinforces The Importance Of MelaFind® As A Diagnostic Tool At AAD Meeting - PR Newswire 03.18.13 | 09:03 am
- Epidemic Increases In Melanoma Rates Three Of Four Americans Surveyed Have Never Had Skin Cancer Examination - PR Newswire 02.21.13 | 07:02 am
- MELA Sciences To Participate In Upcoming 15th Annual Needham Growth Conference - PR Newswire 01.04.13 | 08:01 am
- MELA Sciences Names Rpr Marketing Communications As Its New Agency Of Record - PR Newswire 01.03.13 | 08:01 am
- Potential Shareholder Claims Against Mela Sciences Investigated By Goldfarb Branham Law Firm LLP - Business Wire 12.01.10 | 09:12 am
- The Law Office Of Robbins Umeda LLP Announces An Investigation Of MELA Sciences, Inc. - Business Wire 11.18.10 | 01:11 pm
- Bronstein, Gewirtz & Grossman, LLC Investigating Possible Securities Law Violations At MELA Sciences, Inc. - Business Wire 11.17.10 | 02:11 pm
- Kahn Swick & Foti, LLC And Former Louisiana Attorney General Announce Investigation Into MELA Sciences, Inc. - MELA - Business Wire 11.16.10 | 06:11 pm
Partner Headlines for MELA
- MELA Sciences Pops 10% on Positive Results in German Clinical Study - Benzinga 07.09.12 | 01:07 pm
- MELA Sciences to Sell $20M Shares Through 'at-the-market' Equity Offering Program - Benzinga 06.15.12 | 07:06 pm
- Verisante Technology: The Future Of Cancer Detection - Seeking Alpha 11.21.11 | 08:11 am
- Company News for September 27, 2011 - Corporate Summary - Zacks 09.27.11 | 10:09 am
- Notable Put Options Activity in MELA Sciences - Benzinga 09.27.11 | 09:09 am
- Morning Market Movers - Benzinga 09.26.11 | 09:09 am
- Company News for September 8, 2011 - Corporate Summary - Zacks 09.08.11 | 10:09 am
- Morning Market Movers - Benzinga 09.07.11 | 09:09 am
- 4 Small Caps Likely to Rebound? - Seeking Alpha 12.12.10 | 09:12 am
- Friday Options Recap - Seeking Alpha 11.19.10 | 03:11 pm
